Jefferies Downgrades Hayward Holdings to Hold, Announces $27 Price Target

Jefferies analyst Saree Boroditsky downgrades Hayward Holdings (NYSE:HAYW) from Buy to Hold and announces $27 price target.

byBenzinga Newsdesk

December 20, 2021

1 minute read

Jefferies analyst Saree Boroditsky downgrades Hayward Holdings (NYSE:HAYW) from Buy to Hold and announces $27 price target.

Aquestive Therapeutics Sees FY23 Revenue $37M-$41M Vs $37.83M Est.

By Happy Mohamed

Today, 8:04 AM

2023 Outlook Aquestive is providing its full year 2023 financial outlook. The Company expects: Guidance Total revenue (in millions) $37 to $41 Non-GAAP adjusted EBITDA

AQST

ViacomCBS, Altice USA Report Renewal Of Distribution Deal, No Terms Disclosed

By Benzinga Newsdesk

Today, 8:04 AM

ViacomCBS Inc. (NASDAQ:VIAC, VIACA)) and Altice USA (NYSE:ATUS) today announced a comprehensive agreement for the continued carriage of ViacomCBS’ leading portfolio of broadcast, entertainment, news and sports

ATUS

Wolfe Research Initiates Coverage On Innovative Industrial with Outperform Rating, Announces Price Target of $249

By Benzinga Newsdesk

Today, 8:04 AM

Wolfe Research analyst Andrew Rosivach initiates coverage on Innovative Industrial (NYSE:IIPR) with a Outperform rating and announces Price Target of $249.

IIPR

Pulse Biosciences Says On Feb, 5 Received Letter From FDA In Which FDA Stated It Did Not Believe Co. Provided Sufficient Clinical Evidence To Support Expanded Indication For Use To Expand CellFX System’s Current Labeling

By Bill Haddad

Today, 8:04 AM

Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced an update to its recent

PLSE

Jefferies Downgrades Hayward Holdings to Hold, Announces $27 Price Target

Related Posts

Aquestive Therapeutics Sees FY23 Revenue $37M-$41M Vs $37.83M Est.

ViacomCBS, Altice USA Report Renewal Of Distribution Deal, No Terms Disclosed

Wolfe Research Initiates Coverage On Innovative Industrial with Outperform Rating, Announces Price Target of $249

Pulse Biosciences Says On Feb, 5 Received Letter From FDA In Which FDA Stated It Did Not Believe Co. Provided Sufficient Clinical Evidence To Support Expanded Indication For Use To Expand CellFX System’s Current Labeling